Drug resistance mechanisms in cancer cells: A proteomics perspective

Current Opinion in Molecular Therapeutics

Volumn 5, Issue 3, 2003, Pages 258-265

  Verrills, Nicole M ^a,b   Kavallaris, Maria ^b  

^a MACQUARIE UNIVERSITY   (Australia)

^b CHILDREN S CANCER INSTITUTE AUSTRALIA FOR MEDICAL RESEARCH   (Australia)

Author keywords

Anticancer drugs; Antimicrotubules; Drug resistance; Protein expression; Proteomics

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; COLCHICINE; CYTOTOXIC AGENT; DAUNORUBICIN; DOXORUBICIN; ETOPOSIDE; MITOMYCIN C; MITOXANTRONE; PROTEOME; VINBLASTINE; VINCRISTINE;

BREAST CANCER; CANCER CELL; DRUG MECHANISM; DRUG TARGETING; GENE EXPRESSION PROFILING; HUMAN; KIDNEY CARCINOMA; LEUKEMIA; LUNG CANCER; METHODOLOGY; OVARY CANCER; PAPILLOMA; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN ISOLATION; PROTEIN LOCALIZATION; PROTEIN STRUCTURE; PROTEOMICS; REVIEW; TREATMENT FAILURE; TUMOR CELL;

ANTINEOPLASTIC AGENTS; APOPTOSIS; DRUG RESISTANCE, NEOPLASM; HUMANS; NEOPLASMS; PROTEOME; PROTEOMICS; TREATMENT OUTCOME;

EID: 0141502039     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (79)

1. O'Farrell PH: High resolution two-dimensional electrophoresis of proteins. J Biol Chem (1975) 250(10):4007-4021.
2. Bjellqvist B, Ek K, Righetti PG, Gianazza E, Gorg A, Westermeier R, Postal W: Isoelectric focusing in immobilized pH gradients: Principle, methodology and some applications. J Biochem Biophys Methods (1982) 6(4):317-339.
3. Scherl A, Coute Y, Deon C, Calle A, Kindbeiter K, Sanchez JC, Greco A, Hochstrasser D, Diaz JJ: Functional proteomic analysis of human nucleolus. Mol Biol Cell (2002) 13(11):4100-4109.
4. Aebersold R, Mann M: Mass spectrometry-based proteomics. Nature (2003) 422(6928):198-207.
5. Gygi SP, Rist B, Gerber SA, Turecek F, Gelb MH, Aebersold R: Quantitative analysis of complex protein mixtures using isotope-coded affinity tags. Nat Biotechnol (1999) 17(10):994-999.
6. Hoffmann P, Ji H, Moritz RL, Connolly LM, Frecklington DF, Layton MJ, Eddes JS, Simpson RJ: Continuous free-flow electrophoresis separation of cytosolic proteins from the human colon carcinoma cell line LIM 1215: A non two-dimensional gel electrophoresis-based proteome analysis strategy. Proteomics (2001) 1(7):807-818.
7. Fey SJ, Larsen PM: 2D or not 2D. Two-dimensional gel electrophoresis. Curr Opin Chem Biol (2001) 5(1):26-33.
8. Merchant M, Weinberger SR: Recent advancements in surface-enhanced laser desorption/ionization-time of flight-mass spectrometry. Electrophoresis (2000) 21(6):1164-1177.
9. Xiao Z, Adam BL, Cazares LH, Clements MA, Davis JW, Schellhammer PF, Dalmasso EA, Wright GL Jr: Quantitation of serum prostate-specific membrane antigen by a novel protein biochip immunoassay discriminates benign from malignant prostate disease. Cancer Res (2001) 61(16):6029-6033.
10. Liotta LA, Espina V, Mehta AI, Calvert V, Rosenblatt K, Geho D, Munson PJ, Young L, Wulfkuhle J, Petricoin EF: Protein microarrays: Meeting analytical challenges for clinical applications. Cancer Cell (2003) 3(4):317-325.
11. Phizicky E, Bastiaens PI, Zhu H, Snyder M, Fields S: Protein analysis on a proteomic scale. Nature (2003) 422(6928):208-215.
12. Hanash S: Disease proteomics. Nature (2003) 422(6928):226-232.
13. Celis JE, Gromov P: Proteomics in translational cancer research: Toward an integrated approach. Cancer Cell (2003) 3(1):9-15.
14. Celis JE, Ostergaard M, Jensen NA, Gromova I, Rasmussen HH, Gromov P: Human and mouse proteomic databases: Novel resources in the protein universe. FEBS Lett (1998) 430(1-2):64-72.
15. Alaiya AA, Franzen B, Auer G, Linder S: Cancer proteomics: From identification of novel markers to creation of artifical learning models for tumor classification. Electrophoresis (2000) 21(6):1210-1217.
16. Srinivas PR, Srivastava S, Hanash S, Wright GL Jr: Proteomics in early detection of cancer. Clin Chem (2001) 47(10):1901-1911.
17. Jones MB, Krutzsch H, Shu H, Zhao Y, Liotta LA, Kohn EC, Petricoin EF 3rd: Proteomic analysis and identification of new biomarkers and therapeutic targets for invasive ovarian cancer. Proteomics (2002) 2(1):76-84.
18. Celis JE, Celis P, Palsdottir H, Ostergaard M, Gromov P, Primdahl H, Orntoft TF, Wolf H, Celis A, Gromova I: Proteomic strategies to reveal tumor heterogeneity among urothelial papillomas. Mol Cell Proteomics (2002) 1(4):269-279.
19. Petricoin EF, Ardekani AM, Hitt BA, Levine PJ, Fusaro VA, Steinberg SM, Mills GB, Simone C, Fishman DA, Kohn EC, Liotta LA: Use of proteomic patterns in serum to identify ovarian cancer. Lancet (2002) 359(9306):572-577.
20. Hanash SM, Baier LJ, McCurry L, Schwartz SA: Lineage-related polypeptide markers in acute lymphoblastic leukemia detected by two-dimensional gel electrophoresis. Proc Natl Acad Sci USA (1986) 83(3):807-811.
21. Strahler JR, Kuick R, Eckerskorn C, Lottspeich F, Richardson BC, Fox DA, Stoolman LM, Hanson CA, Nichols D, Tueche HJ at al: Identification of two related markers for common acute lymphoblastic leukemia as heat shock proteins. J Clin Invest (1990) 85(1):200-207.
22. Hanash SM, Kuick R, Strahler J, Richardson B, Reaman G, Stoolman L, Hanson C, Nichols D, Tueche HJ: Identification of a cellular polypeptide that distinguishes between acute lymphoblastic leukemia in infants and in older children. Blood (1989) 73(2):527-532.
23. Voss T, Ahorn H, Haberl P, Dohner H, Wilgenbus K: Correlation of clinical data with proteomics profiles in 24 patients with B-cell chronic lymphocytic leukemia. Int J Cancer (2001) 91(2):180-186.
24. Hanash SM, Baier LJ: Two-dimensional gel electrophoresis of cellular proteins reveals myeloid origin of blasts in two children with otherwise undifferentiated leukemia. Cancer (1986) 57(8):1539-1543.
25. Shin BK, Wang H, Yim AM, Le Naour F, Brichory F, Jang JH, Zhao R, Puravs E, Tra J, Michael CW, Misek DE at al: Global profiling of the cell surface proteome of cancer cells uncovers an abundance of proteins with chaperone function. J Biol Chem (2003) 278(9):7607-7616.
26. Adam PJ, Boyd R, Tyson KL, Fletcher GC, Stamps A, Hudson L, Poyser HR, Redpath N, Griffiths M, Steers G, Terrett JA at al: Comprehensive proteomic analysis of breast cancer cell membranes reveals unique proteins with potential roles in clinical cancer. J Biol Chem (2003) 278(8):6482-6489.
27. Myers TG, Anderson NL, Waltham M, Li G, Buolamwini JK, Scudiero DA, Paull KD, Sausville EA, Weinstein JN: A protein expression database for the molecular pharmacology of cancer. Electrophoresis (1997) 18(3-4):647-653.
28. Hutter G, Sinha P: Proteomics for studying cancer cells and the development of chemoresistance. Proteomics (2001) 1(10):1233-1248.
29. Sinha P, Hutter G, Kottgen E, Dietel M, Schadendorf D, Lage H: Increased expression of annexin I and thiaredoxin detected by two-dimensional gel electrophoresis of drug resistant human stomach cancer cells. J Biochem Biophys Methods (1998) 37(3):105-116.
30. Sinha P, Hutter G, Kottgen E, Dietel M, Schadendorf D, Lage H: Search for novel proteins involved in the development of chemoresistance in colorectal cancer and fibrosarcoma cells in vitro using two-dimensional electrophoresis, mass spectrometry and microsequencing. Electrophoresis (1999) 20(14):2961-2969.
31. Sinha P, Kohl S, Fischer J, Hutter G, Kern M, Kottgen E, Dietel M, Lage H, Schnolzer M, Schadendorf D: Identification of novel proteins associated with the development of chemoresistance in malignant melanoma using two-dimensional electrophoresis. Electrophoresis (2000) 21(14):3048-3057.
32. Sinha P, Hutter G, Kottgen E, Dietel M, Schadendorf D, Lage H: Increased expression of epidermal fatty acid binding protein, cofilin, and 14-3-3-σ (stratifin) detected by two-dimensional gel electrophoresis, mass spectrometry and microsequencing of drug-resistant human adenocarcinoma of the pancreas. Electrophoresis (1999) 20(14):2952-2960.
33. Prasad SC, Soldatenkov VA, Kuettel MR, Thraves PJ, Zou X, Dritschilo A: Protein changes associated with ionizing radiation-induced apoptosis in human prostate epithelial tumor cells. Electrophoresis (1999) 20(4-5):1065-1074.
34. Crowley-Weber CL, Payne CM, Gleason-Guzman M, Watts GS, Futscher B, Waltmire CN, Crowley C, Dvorakova K, Bernstein C, Craven M, Garewal H at al: Development and molecular characterization of HCT-116 cell lines resistant to the tumor promoter and multiple stress-inducer, deoxycholate. Carcinogenesis (2002) 23(12):2063-2080.
35. Hathout Y, Riordan K, Gehrmann M, Fenselau C: Differential protein expression in the cytosol fraction of an MCF-7 breast cancer cell line selected for resistance toward melphalan. J Proteome Res (2002) 1(5):435-442.
36. Nishio K, Sugimoto Y, Kasahara K, Fujiwara Y, Nishiwaki S, Fujiki H, Ohata M, Saijo N: Increased phosphorylation of nuclear phosphoproteins in human lung-cancer cells resistant to cisdiamminedichloroplatinum (II). Int J Cancer (1992) 50(3):438-442.
37. Ji H, Baldwin GS, Burgess AW, Moritz RL, Ward LD, Simpson RJ: Epidermal growth factor induces serine phosphorylation of stathmin in a human colon carcinoma cell line (LIM 1215). J Biol Chem (1993) 268(18):13396-13405.
38. Kavallaris M, Verrills NM, Hill BT: Anticancer therapy with novel tubulin-interacting drugs. Drug Resist Updat (2001) 4(6):392-401.
39. Drukman S, Kavallaris M: Microtubule alterations and resistance to tubulin-binding agents. Int J Oncol (2002) 21(3):621-628.
40. Anderson NL, Anderson NG: Proteome and proteomics: New technologies, new concepts, and new words. Electrophoresis (1998) 19(11):1853-1861.
41. Cabral F, Sobel ME, Gottesman MM: CHO mutants resistant to colchicine, colcemid or griseofulvin have an altered β-tubulin. Cell (1980) 20(1):29-36.
42. Cabral F, Abraham I, Gottesman MM: Isolation of a taxol-resistant Chinese hamster ovary cell mutant that has an alteration in α-tubulin. Proc Natl Acad Sci USA (1981) 78(7):4388-4391.
43. Gonzalez-Garay ML, Chang L, Blade K, Menick DR, Cabral F: A β-tubulin leucine cluster involved in microtubule assembly and paclitaxel resistance. J Biol Chem (1999) 274(34):23875-23882.
44. Kavallaris M, Tait AS, Walsh BJ, He L, Horwitz SB, Norris MD, Haber M: Multiple microtubule alterations are associated with Vinca alkaloid resistance in human leukemia cells. Cancer Res (2001) 61(15):5803-5809.
45. Verrills NM, Flemming C, Liu M, Ivery MT, Cobon GS, Norris MD, Haber M, Kavallaris M: Microtubule alterations and mutations induced by desoxyepothilone B: Implications for drug-target interactions. Chem Biol (2003): in press.
46. Martello LA, Verdier-Pinard P, Shen HJ, He L, Torres K, Orr GA, Horwitz SB: Elevated levels of microtubule destabilizing factors in a taxol-resistant/dependent A549 cell line with an α-tubulin mutation. Cancer Res (2003) 63(6):1207-1213.
47. Burkhart CA, Kavallaris M, Band Horwitz S: The role of β-tubulin isotypes in resistance to antimitotic drugs. Biochim Biophys Acta (2001) 1471(2):O1-O9.
48. Lee WP: Purification and characterization of tubulin from parental and vincristine-resistent HOB1 lymphoma cells. Arch Biochem Biophys (1995) 319(2):498-503.
49. Rao S, Aberg F, Nieves E, Band Horwitz S, Orr GA: Identification by mass spectrometry of a now α-tubulin isotype expressed in human breast and lung carcinoma cell lines. Biochemistry (2001) 40(7):2096-2103.
50. Boucher D, Larcher JC, Gros F, Denoulet P: Polyglutamylation of tubulin as a progressive regulator of in vitro interactions between the microtubule-associated protein Tau and tubulin. Biochemistry (1994) 33(41):12471-12477.
51. Larcher JC, Boucher D, Lazereg S, Gros F, Denoulet P: Interaction of kinesin motor domains with α- and β-tubulin subunits at a tau-independent binding site. Regulation by polyglutamylation. J Biol Chem (1996) 271(36):22117-22124.
52. Banerjee A: Increased levels of tyrosinated α-, β(III)-, and β(IV)-tubulin isotypes in paclitaxel-resistent MCF-7 breast cancer cells. Biochem Biophys Res Commun (2002) 293(1):598-601.
53. Banerjee A: Coordination of posttranslational modifications of bovine brain α-tubulin. Polyglycylation of δ2 tubulin. J Biol Chem (2002) 277(48):46140-46144.
54. Melhem RF, Zhu XX, Hailat N, Strahler JR, Hanash SM: Characterization of the gene for a proliferation-related phosphoprotein (oncoprotein 18) expressed in high amounts in acute leukemia. J Biol Chem (1991) 266(27):17747-17753.
55. Melhem R, Hailat N, Kuick R, Hanash SM: Quantitative analysis of Op18 phosphorylation in childhood acute leukemia. Leukemia (1997) 11(10):1690-1695.
56. Hailat N, Strahler J, Melhem R, Zhu XX, Brodeur G, Seeger RC, Reynolds CP, Hanash S: N-myc gene amplification in neuroblastoma is associated with altered phosphorylation of a proliferation related polypeptide (Op18). Oncogene (1990) 5(11):1615-1618.
57. Kavallaris M, Burkhart CA, Horwitz SB: Antisense oligonucleotides to class III β-tubulin sensitize drug-resistant cells to Taxol. Br J Cancer (1999) 80(7):1020-1025.
58. Iancu C, Mistry SJ, Arkin S, Atweh GF: Taxol and anti-stathmin therapy: A synergistic combination that targets the mitotic spindle. Cancer Res (2000) 60(13):3537-3541.
59. Mandelkow E, Mandelkow EM: Microtubules and microtubule-associated proteins. Curr Opin Cell Biol (1995) 7(1):72-81.
60. Lee VM: Disruption of the cytoskeleton in Alzheimer's disease. Curr Opin Neurobiol (1995) 5(5):663-668.
61. 2+/calmodulin-dependent protein kinase II in its tubulin binding sites. Arch Biochem Biophys (2002) 408(2):255-262.
62. Veitia R, Bissery MC, Martinez C, Fellous A: Tau expression in model adenocarcinomas correlates with docetaxel sensitivity in tumour-bearing mice. Br J Cancer (1998) 78(7):871-877.
63. Sangrajrang S, Denoulet P, Millot G, Tatoud R, Podgomiak MP, Tew KD, Calvo F, Fellous A: Estramustine resistance correlates with tau over-expression in human prostatic carcinoma cells. Int J Cancer (1998) 77(4):626-631.
64. Baas PW, Pienkowski TP, Cimbalnik KA, Toyama K, Bakalis S, Ahmad FJ, Kosik KS: Tau confers drug stability but not cold stability to microtubules in living cells. J Cell Sci (1994) 107(Pt 1):135-143.
65. Guise S, Braguer D, Remacle-Bonnet M, Pommier G, Briand C: Tau protein is involved in the apoptotic process induced by anti-microtubule agents on neuroblastoma cells. Apoptosis (1999) 4(1):47-58.
66. Guise S, Braguer D, Carles G, Delacourte A, Briand C: Hyperphosphorylation of tau is mediated by ERK activation during anticancer drug-induced apoptosis in neuroblastoma cells. J Neurosci Res (2001) 63(3):257-267.
67. Igney FH, Krammer PH: Death and anti-death: Tumour resistance to apoptosis. Nat Rev Cancer (2002) 2(4):277-288.
68. Prasad S, Soldatenkov VA, Srinivasarao G, Dritschilo A: Identification of keratins, 18, 19 and heat-shock protein 90 as candidate substrates of proteolysis during ionizing radiation-induced apoptosis of estrogen-receptor negative breast tumor cells. Int J Oncol (1998) 13(4):757-764.
69. Moller A, Malerczyk C, Volker U, Stoppler H, Maser E: Monitoring daunorubicin-induced alterations in protein expression in pancreas carcinoma cells by two-dimensional gel electrophoresis. Proteomics (2002) 2(6):697-705.
70. Brockstedt E, Rickers A, Kostka S, Laubersheimer A, Dorken B, Wittmann-Liebold B, Bommert K, Otto A: Identification of apoptosis-associated proteins in a human Burkitt lymphoma cell line. Cleavage of heterogeneous nuclear ribonucleoprotein A1 by caspase 3. J Biol Chem (1998) 273(43):28057-28064.
71. Gerner C, Seelos C, Sauermann G: Alteration of nuclear matrix protein composition during apoptosis in rat embryo cells. Exp Cell Res (1998) 238(2):472-480.
72. Gerner C, Frohwein U, Gotzmann J, Bayer E, Gelbmann D, Bursch W, Schulte-Hermann R: The Fas-induced apoptosis analyzed by high throughput proteome analysis. J Biol Chem (2000) 275(50):39018-39026.
73. Gottesman MM, Pastan I: Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem (1993) 62:385-427.
74. Sikic BI: Modulation of multidrug resistance: At the threshold. J Clin Oncol (1993) 11(9):1629-1635.
75. Shabbits JA, Krishna R, Mayer LD: Molecular and pharmacological strategies to overcome multidrug resistance. Expert Rev Anticancer Ther (2001) 1(4):585-594.
76. Borchers C, Boer R, Klemm K, Figala V, Denzinger T, Ulrich WR, Haas S, Ise W, Gekeler V, Przybylski M: Characterization of the dexniguldipine binding site in the multidrug resistance-related transport protein P-glycoprotein by photoaffinity labeling and mass spectrometry. Mol Pharmacol (2002) 61(6):1366-1376.
77. Araki N, Morimasa T, Sakai T, Tokuoh H, Yunoue S, Kamo M, Miyazaki K, Abe K, Saya H, Tsugita A: Comparative analysis of brain proteins from p53-deficient mice by two-dimensional electrophoresis. Electrophoresis (2000) 21(9):1880-1889.
78. Weinstein JN, Myers TG, O'Connor PM, Friend SH, Fornace AJ Jr, Kohn KW, Fojo T, Bates SE, Rubinstein LV, Anderson NL, Buolamwini JK at al: An Information-intensive approach to the molecular pharmacology of cancer. Science (1997) 275(5298):343-349.
79. Chung CH, Bernard PS, Peron CM: Molecular portraits and the family tree of cancer. Nat Genet (2002) 32(Suppl):533-540.